Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment: the decision to establish a ...

A major cyberattack on CDK Global, a software service used by thousands of car dealerships, is now impacting the public. The ...

A pair of cyberattacks against software maker CDK continues to impact thousands of car dealerships and has spurred threat actors to launch impersonation attacks. The CDK Global outage affecting ...

The night before June 19, Brian MacDonald attended a hockey game. The CDK Global CEO owns a home in Florida, and he capped his day driving two hours to see the Florida Panthers face off against ...

DelveInsight's CDK 7 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

CDK Global's agreement to pay $100 million to resolve a class-action antitrust lawsuit has earned preliminary approval from an Illinois federal judge. Affected dealerships should start receiving ...